Berkshire Hathaway sold these stocks last quarter, and that could mean you should sell them, too.
Here's which one of these large-cap biotechs put up the best numbers in the first quarter.
These were Berkshire Hathaway's biggest buys in the first quarter.
The price slipped on news of a share offering by one of its biggest investors.
Cannabis company Tilray's latest financial report includes plenty of pros and cons.
Canada's second-biggest marijuana stock by revenue is growing rapidly, but losses continue.
CannTrust's got big plans that could turn it into one of Canada's top pot stocks.
These cancer drug developers could report market-moving news soon.
Its been a tough few years for investors in this big-cap biotech, but signals are emerging that better days are ahead.
A new study is planned that could someday reshape colon cancer screenings.
Here's what you should know about this fast-growing cannabis company following its latest quarterly financial results.
Sales slipped from the fourth quarter, but there's still a lot to like about this company.
The company's still struggling to transition from clinical stage to commercial stage, but it's making progress.
First-quarter financial results are failing to spark investor optimism on concerns over cash burn.
This big-cap biotech has a problem or two on its hands.
GW Pharmaceuticals reported surging sales last quarter, but investors ought to be aware of a lot more than that.
This drugmaker's cannabidiol formulation could become more widely used following positive phase 3 trial results in tuberous sclerosis complex.
The company is one step closer to securing an OK for its new cholesterol-busting drug.
Anemic second-quarter financials have investors reining in their expectations.
These two disruptive companies reported crazy-good top-line growth, but only one can be the winner.